Mary Kay Inspires Beauty Trends at Spring/Summer 2020 Fashion Weeks in Europe
20.12.2019 02:06:00 EET | Business Wire | Press release
Mary Kay Inc. continues to make its mark on the beauty industry through its ongoing partnerships with Ukrainian and Belarus Fashion Weeks, Mercedes-Benz Fashion Week Russia, and Bratislava Fashion Days in Slovakia and Czech Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191219005838/en/
Mercedes-Benz Fashion Week Russia (Photo: Mary Kay Inc.)
“As an innovator of beauty trends, Mary Kay along with beauty artists, unveiled 2020 runway looks throughout fashion weeks in Europe,” stated Tara Eustace, President of Mary Kay for the European Region. “The runways at fashion week are the perfect stage to share inspiration, debut our innovations with the fashion world and elevate makeup trends in each of these countries.”
Designers, influencers, celebrities, makeup artists, beauty bloggers and editors attended all five events where Mary Kay was the official beauty partner for the spring/summer 2020 fashion week season.
“The Mary Kay Global Design Studio was created over 10 years ago to inspire beauty trends and drive innovation, fueling creativity and individuality through fashion collaborations around the world,” said Sheryl Adkins-Green, Chief Marketing Officer, and Creative & Inspiration Officer for the Mary Kay Global Design Studio. “During fashion weeks, makeup artists in collaboration with Mary Kay, unleashed some of the major trends of the season. Beauty enthusiasts can get the look ‘as seen’ on the runway or revisit the inspiration to create their own.”
Fashion Weeks Highlights:
Held in Kyiv between August 31-September 4, 2019, Ukrainian Fashion Week (UFW) kicked off the Mary Kay sponsored events in Europe. Under the artistic direction of lead makeup artist MartElle, a team of 40 beauty artists, all of whom are also members of the Mary Kay independent sales force, prepped the runway models for 30 Ukrainian designers and performed 350 different makeup looks throughout UFW. One of the fashion shows was an exclusive capsule pink bra collection collaboration between Mary Kay Ukraine and lingerie brand Keòsme aimed at supporting women diagnosed with breast cancer. Ten percent of sales proceeds from the exclusive collection will be donated to a Ukrainian nonprofit organization that promotes female health and wellness.
Bratislava Fashion Days by Mercedes-Benz was next in Bratislava on September 16-19, and Prague on October 5-6. For the second year in a row, Mary Kay Slovakia was the Official Makeup Artist for the event. Makeup artists prepared the show-stopping makeup looks worn by runway models and starred in the backstage stories on Fashion TV. Inspired by Mary Kay’s Global Beauty Ambassador Luis Casco, the “Sparkling Pewter,” “Sultry Glam,” “Sweet Champagne,” and “Garnet Gold” special looks became the highlights of the shows. The December 17 show in Bratislava marked the closing of the 2019 edition of the Fashion Days.
Mary Kay Russia has been the Official Makeup Artist of the Mercedes-Benz Fashion Week Russia (MBFW Russia) for 7 years in a row—13 consecutive seasons. The largest fashion event in Eastern Europe, MBFW Russia was held in Moscow on October 15-19. Luis Casco, and star makeup artist Andrey Shilkov, co-created the looks for 109 shows out of a total of 119, while a makeup team from the Mary Kay Russia independent sales force represented the brand backstage. The stunning beauty look imagined for the Te Amo Couture runway show was the result of the exclusive Casco-Shilkov collaboration.
The Belarus Fashion Week (BFW) held in Minsk on October 17- 20, 2019, wrapped up a successful fashion week season for Mary Kay in Eastern Europe. Mary Kay was BFW Official Makeup Artist for the 7th season in a row. A team of beauty artists from the Mary Kay Belarus independent sales force featured 650 runway looks and no less than 500 makeovers under the guidance of beauty artist maestro Alexander Kiryniuk, who also presented the season's trends.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191219005838/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom